GET DAILY SIGNALSAzitra (AZTR) Stock Declines -34.5% Over 30 Days After Reverse Split
Key Takeaways
- Azitra shares fell roughly 34.5% over the past 30 days, from a split-adjusted close of about $1.70 to approximately $1.11, despite a brief single-day surge on new cosmetic-program data.
- The decline reflects a prolonged slide into penny-stock territory and a 1-for-10 reverse stock split that became effective on October 26, 2026.
- A short-lived rally followed October 26 ex vivo results for ATR-COSF, which showed a roughly 50% reduction in the appearance of wrinkles after 48 hours.
- Over the trailing three months, the stock is down about 14.7%, having peaked near $1.86 in late August before trending lower through September and October.
- Clinical progress continued, including ATR-04 advancing to the second cohort of its Phase 1/2 study in EGFR inhibitor-associated skin rash.
- The company also suspended its at-the-market offering program and retains a small market capitalization near $9 million.
- For additional context on valuation and fundamentals, explore Azitra's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are monitoring tickers like AZTR.
Azitra (AZTR) Company Overview and Market Position
Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology. Headquartered in Branford, Connecticut, and founded in 2014, the company develops engineered proteins and topical live biotherapeutic products built on Staphylococcus epidermidis to treat skin diseases. Its lead therapeutic candidate, ATR-12, is in Phase 1b/2a development for Netherton syndrome, a rare genetic skin disorder. The company is also advancing ATR-04, a Fast Track-designated candidate for the skin rash associated with EGFR inhibitor cancer therapy, and ATR-01 for ichthyosis vulgaris. Azitra maintains a joint development agreement with Bayer and a proprietary microbial library of roughly 1,500 unique strains. Investors follow the stock for its rare-disease pipeline and dermatology platform, though as a pre-revenue, clinical-stage company it carries elevated financing and execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Azitra (AZTR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Azitra shares declined approximately 34.5%, moving from a split-adjusted close of $1.695 in late September to about $1.11 in late October. The path was far from linear: the stock slid steadily through the first half of October before a dramatic single-session rebound on October 26, followed by renewed selling pressure.
Looking at the broader three-month period, the stock is down roughly 14.7%, from a split-adjusted close near $1.30 in late July to about $1.11. The quarterly trend peaked in late August, when shares reached approximately $1.86, before a sustained retreat into September and October. All figures are adjusted for the 1-for-10 reverse stock split to provide a like-for-like comparison.
What Drove AZTR Stock Price in the Last 30 Days
The dominant driver was a prolonged decline that pushed the shares into penny-stock territory. In mid-October, the company announced a 1-for-10 reverse stock split, approved by the board on October 14 and effective October 26, reducing the issued share count from about 60.6 million to roughly 6.06 million. The move was aimed at regaining compliance with NYSE American continued-listing requirements, and it underscored the pressure the stock had faced.
On the clinical front, Azitra reported on October 1 that its Phase 1/2 trial of ATR-04 had completed the first cohort and that the safety review committee recommended advancing to cohort 2. On October 26, the company released ex vivo data for ATR-COSF, a cosmetic candidate, showing a roughly 50% reduction in the appearance of wrinkles 48 hours after a single application. The stock surged more than 100% intraday on the news, and the company separately announced the suspension of its at-the-market offering program. The rally proved short-lived, however, and shares pulled back sharply in subsequent sessions as investors weighed the early-stage nature of the data against the company's small market capitalization and financing needs.
What Drove AZTR Stock Performance Over the Last Quarter
The broader multi-month narrative centers on a clinical-stage company contending with a declining share price and a shrinking capital base. After reaching a late-August high near $1.86, the stock lost momentum through September and October as financing concerns mounted and the shares drifted toward a dollar threshold that triggered the reverse stock split. The capital-structure reset, combined with the early-stage ATR-COSF data and the ATR-04 cohort advancement, shaped the quarter's overall trajectory: sustained weakness punctuated by brief, news-driven spikes in volatility.
AZTR Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape Azitra's share price in the months ahead. The company has said initial human clinical data for ATR-COSF is anticipated before the end of 2026, with additional details expected at the BIO-Europe conference in November. Continued enrollment and safety readouts from the ATR-04 Phase 1/2 cohort 2 will also be closely watched, as will progress on ATR-12 for Netherton syndrome. On the financial side, the company's small market capitalization, pre-revenue status, and need for additional funding remain key risk factors, particularly given the recent suspension of its at-the-market offering program and the possibility that it may pursue other financing transactions. Investors should monitor clinical milestones, regulatory developments, and capital-raising activity rather than relying on short-term price swings. From what I see, this is important because clinical updates and funding moves often dictate near-term direction for names like AZTR.
Exploring AI Tools in My Research Process
One resource I turn to regularly is Tickeron’s AI Trading Bots, which provides a marketplace of hundreds of bots trading thousands of tickers. I find the filtered view of top-performing strategies helpful when assessing volatile small-cap names, as it highlights data-driven approaches ranging from short-term momentum to longer technical models. This adds a useful layer when tracking price action in names like AZTR.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZTR in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 34 cases where AZTR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 50 cases where AZTR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AZTR as a result. In 44 of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for AZTR just turned positive on October 26, 2026. Looking at past instances where AZTR's MACD turned positive, the stock continued to rise in 24 of 30 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 116 of 144 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZTR moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 9 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
AZTR moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AZTR crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AZTR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AZTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.642) is normal, around the industry mean (2.974). AZTR has a moderately high P/E Ratio (76.500) as compared to the industry average of (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement